Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methyl 4-bromo-N-[8-(hydroxyamino)-8-oxooctanoyl]-L-phenylalaninate
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Methyl 4-bromo-N-[8-(hydroxyamino)-8-oxooctanoyl]-L-phenylalaninate is a synthetic small molecule characterized by a hydroxamic acid moiety, a structural feature commonly found in histone deacetylase (HDAC) inhibitors. This compound, or closely related biarylalanine-containing hydroxamic acids, has shown subtype selectivity for Histone Deacetylase 6 (HDAC6). HDACs are enzymes that remove acetyl groups from histone and non-histone proteins, playing a crucial role in epigenetic regulation of gene expression and various cellular processes. By inhibiting HDAC6, this compound is expected to modulate gene expression, which can lead to anti-proliferative effects, making it a potential candidate for therapeutic applications, particularly in oncology. The X-ray crystal structure of a related HDAC6-selective inhibitor bound to a bacterial deacetylase (HDAH) has been determined, providing insights into its binding mechanism.
- Other names
- Methyl 4-Bromo-N-[8-(Hydroxyamino)-8-Oxooctanoyl]-L-Phenylalaninatemethyl (2S)-3-(4-bromophenyl)-2-[7-(hydroxycarbamoyl)heptanamido]propanoate
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on methyl 4-bromo-N-[8-(hydroxyamino)-8-oxooctanoyl]-L-phenylalaninate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methyl 4-bromo-N-[8-(hydroxyamino)-8-oxooctanoyl]-L-phenylalaninate.